Literature DB >> 12454214

Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis.

Coen A Stegeman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12454214     DOI： 10.1093/ndt/17.12.2077

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  14 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis.

Authors:  J G M C Damoiseaux; M C Slot; M Vaessen; C A Stegeman; P Van Paassen; J W Cohen Tervaert
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

3.  [Episodic progressive bilateral visual deterioration].

Authors:  S Heinzelmann; F Staubach; W A Lagrèze
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

Review 4.  Risk factors for treatment failures in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis.

Authors:  Vijay R Karia; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

5.  Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies.

Authors:  Qian Sun; Boris Calderon; Zhen Zhao
Journal:  Clin Chim Acta       Date:  2017-05-08       Impact factor: 3.786

6.  Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.

Authors:  J-S F Sanders; M G Huitma; C G M Kallenberg; C A Stegeman
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

7.  Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies.

Authors:  Magdalena Mosakowska; Dorota Brodowska Kania; Katarzyna Szamotulska; Aleksandra Rymarz; Stanisław Niemczyk
Journal:  BMC Nephrol       Date:  2021-08-26       Impact factor: 2.388

8.  Diagnostic value of antineutrophil cytoplasmic antibodies in children with bronchiolitis obliterans.

Authors:  Dehui Chen; Na Xie; Yuneng Lin; Zifeng Yang; Wenkuan Liu; Shangzhi Wu; Jingbin Chen; Xiaoan Pan; Shaolin Yang; Yong Cai
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

9.  ANCA-GBM dot-blot: evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis.

Authors:  Abraham Rutgers; Jan Damoiseaux; Caroline Roozendaal; Pieter C Limburg; Coen A Stegeman; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

10.  Genetically distinct subsets within ANCA-associated vasculitis.

Authors:  Paul A Lyons; Tim F Rayner; Sapna Trivedi; Julia U Holle; Richard A Watts; David R W Jayne; Bo Baslund; Paul Brenchley; Annette Bruchfeld; Afzal N Chaudhry; Jan Willem Cohen Tervaert; Panos Deloukas; Conleth Feighery; Wolfgang L Gross; Loic Guillevin; Iva Gunnarsson; Lorraine Harper; Zdenka Hrušková; Mark A Little; Davide Martorana; Thomas Neumann; Sophie Ohlsson; Sandosh Padmanabhan; Charles D Pusey; Alan D Salama; Jan-Stephan F Sanders; Caroline O Savage; Mårten Segelmark; Coen A Stegeman; Vladimir Tesař; Augusto Vaglio; Stefan Wieczorek; Benjamin Wilde; Jochen Zwerina; Andrew J Rees; David G Clayton; Kenneth G C Smith
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.